Posted by Michael Wonder on 23 Mar 2023
PHARMAC considers funding rituximab for IgG4 related disease
23 March 2023 - PHARMAC has initiated a consultation today on widening funded access to rituximab (branded as Riximyo) for people with IgG4 related disease, a chronic inflammatory condition.
“PHARMAC currently funds rituximab for several indications including cancer, rheumatoid arthritis, and autoimmune and blood conditions,” says PHARMAC’s Chief Medical Officer Dr David Hughes.
“While IgG4 related disease is uncommon and has only recently been identified, our Pharmacology and Therapeutics Advisory Committee have recommended it for funding with a high priority.”
